Olaparib and pancreatic cancer: A challenging Lesson

被引：1
|
作者：
Louvet, Christophe [1 ]
Samalin, Emmanuelle [2 ]
Michel, Pierre [3 ]
机构：
[1] Inst Mutualiste Montsouris, Dept Med Oncol, F-75014 Paris, France
[2] Univ Montpellier, Inst Canc Montpellier Val Aurelle, Unite Oncol Gigest, Grp Digestif Unicanc, F-34298 Montpellier 5, France
[3] Normandie Univ, Hop Univ Rouen, Serv Hepatogastroenterol, UNIROUEN,Inserm 1245,IRON Grp,FFCD, F-76000 Rouen, France
来源：
BULLETIN DU CANCER | 2019年 / 106卷 / 09期
关键词：
D O I：
10.1016/j.bulcan.2019.07.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：715 / 716
页数：2
相关论文
共 50 条
  • [31] Challenging pancreatic cancer-prone pedigrees: A nosologic dilemma
    Lynch, HT
    Deters, CA
    Lynch, JF
    Brand, RA
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (12): : 3062 - 3070
  • [32] Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer
    Quinonero, Francisco
    Parra-Torrejon, Belen
    Ramirez-Rodriguez, Gloria B.
    Garces, Victor
    Delgado-Lopez, Jose M.
    Jimenez-Luna, Cristina
    Perazzoli, Gloria
    Prados, Jose
    Ortiz, Raul
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 5075 - 5093
  • [33] Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
    Mukherjee, Shibani
    Asaithamby, Aroumougame
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2154 - 2156
  • [34] Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer
    Oh, Do-Youn
    Park, Joon Oh
    Kindler, Hedy L.
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Arnold, Dirk
    Reinacker-Schick, Anke
    Tortora, Giampaolo
    Algul, Hana
    O'Reilly, Eileen M.
    McGuiness, David
    Liu, Yu-Zhen
    Cui, Karen
    Schlienger, Katia
    Locker, Gershon Y.
    Golan, Talia
    ANNALS OF ONCOLOGY, 2021, 32 : S319 - S319
  • [35] Challenging the pancreatic cancer:Synthesis and high anti-pancreatic cancer stem cell activity of BE-43547A2
    Science Foundation in China, 2017, (04) : 7 - 7
  • [36] Stroma A Double-Edged Sword in Pancreatic Cancer: A Lesson From Targeting Stroma in Pancreatic Cancer With Hedgehog Signaling Inhibitors
    Gu, Jichun
    Saiyin, Hexige
    Fu, Deliang
    Li, Ji
    PANCREAS, 2018, 47 (04) : 382 - 389
  • [37] Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
    Wu, Bin
    Shi, Lizheng
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (11): : 1528 - +
  • [38] Metformin use does not increase survival of pancreatic cancer patients: A cautionary lesson
    Chaiteerakij, Roongruedee
    Zhen, David B.
    Burch, Patrick A.
    Chaffee, Kari G.
    Bamlet, William R.
    Oberg, Ann L.
    Roberts, Lewis R.
    Petersen, Gloria M.
    CANCER RESEARCH, 2015, 75
  • [39] POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).
    Schwartz, Lawrence Howard
    Kindler, Hedy L.
    Hammel, Pascal
    Reni, Michele
    Van Cutsem, Eric
    Macarulla, Teresa
    Hall, Michael J.
    Park, Joon Oh
    Hochhauser, Daniel
    Arnold, Dirk
    Oh, Do-Youn
    Reinacher-Schick, Anke
    Tortora, Giampaolo
    Alguel, Hana
    O'Reilly, Eileen Mary
    Fromageau, Jeremie
    Ghiorghiu, Dana C.
    McGuinness, David
    Locker, Gershon Y.
    Golan, Talia
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
    Yang, Xueli
    Ndawula, Charles, Jr.
    Zhou, Haiyan
    Gong, Xiaohai
    Jin, Jian
    ONCOLOGY LETTERS, 2015, 9 (02) : 757 - 761
12345